CQE, Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
Org Biomol Chem. 2019 Mar 6;17(10):2579-2593. doi: 10.1039/c8ob02902d.
Photodynamic therapy (PDT) combines a photosensitizer (PS) with the physical energy of non-ionizing light to trigger cell death pathways. PDT has potential as a therapeutic modality to be used in alternative or in combination with other conventional cancer treatment protocols (e.g. surgery, chemotherapy and radiotherapy). Still, due to the lack of specificity of the current PSs to target the tumor cells, several studies have exploited their conjugation with targeting moieties. PSs conjugated with antibodies (Abs) or their fragments, able to bind antigens overexpressed in the tumors, have demonstrated potential in PDT of tumors. This review provides an overview of the most recent advances on photoimmunoconjugates (PICs) for cancer PDT, which involve the first and second-generation PSs conjugated to Abs. This is an update of our previous review "Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications", published in 2015 in Org. Biomol. Chem.
光动力疗法（PDT）将光敏剂（PS）与非电离光的物理能量相结合，触发细胞死亡途径。PDT 有潜力作为一种治疗方式，与其他传统癌症治疗方案（如手术、化疗和放疗）联合使用或替代使用。然而，由于当前 PS 缺乏针对肿瘤细胞的特异性，因此许多研究都利用它们与靶向部分的结合。与在肿瘤中过度表达的抗原结合的抗体（Abs）或其片段结合的 PS 已被证明在肿瘤 PDT 中有应用潜力。本文综述了近年来涉及第一代和第二代 PS 与 Abs 偶联的光免疫偶联物（PICs）在癌症 PDT 中的最新进展。这是对我们之前在 2015 年发表在 Org. Biomol. Chem.上的综述“武装有光敏剂的抗体：从化学合成到光生物学应用”的更新。
